Construction and effective utilization of biometric Big Data.


Mechanism for new co-creation as the Hub of talents and assets.

Corundum Systems Biology takes on a challenge to create and guide the new era for the human race.


To serve as the Innovation-Hub where the world’s best knowledge and intelligence on life science research is assembled to create innovations for the future of the human race through the approach that perceives the complexity of the human body as a system.

Further, to revitalize Japan through creation of new industries as the Hub to connect Japan’s industry-academia-government activities, conducted in the hope of becoming the scientific and technological nation, with global innovation eco-systems.





NameCorundum Systems Biology Inc.
EstablishedApril 30, 2020
Management Team
CEOHidehiko Otake
Executive DirectorYasushi Yamamoto
Executive DirectorYasunobu Tanaka
Auditor Kenji Takeda
AdvisorEran Segal
Address 1-14-5-N711, Akasaka, Minato-ku, Tokyo 107-0052 Japan
Business domain Develop new businesses in the field of microbiome
Develop biometric database related to microbiome
Support R&D related to microbiome



CEO from April 2020. Hidehiko started his career at the Tokyo office of Bain & Company, a US management consulting firm, and moved to JWT, WPP Group’s advertising agency, where he oversaw corporate strategy and marketing strategy in fields such as medical device, pharmaceutical, beverage and automotive clients. Subsequently, he became a founder and CEO of two bio-technology start-up companies with St. Marianna University School of Medicine. He joined Kantar Japan in 2011 and led marketing strategy projects for various FMCG companies as CEO. Hidehiko graduated from the University of Tokyo (International Relations) , Harvard Business School (MBA) and the Graduate School of Pharmaceutical Sciences of the University of Tokyo.

Yasushi Yamamoto, Executive Director

Executive Board from April 2020. Yasushi worked for Sumitomo Corporation, Japanese top tier Sogo Shosha, and experienced management positions in life science segment in diversified locations such as Ivory Coast, France and Australia. Since 2005, Yamamoto represents Israeli corporations in Japan and has more than 15 years of experience of promoting open innovation between Israel and Japan.  He established Corundum Innovation Ltd with the aim of creating great value captured from the network of Israeli entrepreneurship and Japanese business community in 2014. Yasushi graduated from Kyoto University (faculty of economics).

Yasunobu Tanaka, Ph.D., R.Ph., Executive Director

Yasunobu Tanaka, Ph.D., R.Ph. is Executive Director at Corundum Systems Biology (CSB) since September 2020. In this capacity, he is responsible for business development across CSB. Before joining CSB, Dr. Tanaka started his carrier at Nitto Denko, where he was in charge of liposomal siRNA drug program for liver and lung fibrosis indication. During this program period, he played main roles of global clinical development at phase1/2 stage, IP portfolio management and due diligence that eventually led to successful license out to mega pharma. Dr. Tanaka received his Bachelor and Ph.D. from School of Pharmaceutical Sciences, Osaka University.

Kenji Takeda, PhD, Auditor

Advisor from April 2020 and Auditor from December 2020. Takeda worked for Hitachi, Ltd., the biggest electronics company in Japan, and served as its Vice President of New Business Creation, and as SVP and CTO of Hitachi America Ltd. Furthermore, he proposed, established and managed the Hitachi CVC in the Silicon Valley, USA as the President of The Hitachi Corporate Ventures Catalyst Fund. From 2005 until 2011, he worked as the Executive Director at RIKEN, the Japanese flagship science research institute responsible for innovation. Kenji co-founded and manages Corundum Innovation Co. Ltd as CTO. he has been teaching entrepreneurship as a visiting professor of graduate school of Waseda University since 2004. He received a Bachelor’s, Master’s and Doctor’s degree in engineering from the University of Tokyo and received a Master of Science from MIT.

Professor Eran Segal, PhD, Advisor

Professor Segal serves on the Scientific Advisory Board from April 2020. He heads a multi-disciplinary team at the Department of Computer Science & Applied Mathematics at the Weizmann Institute of Science, continuing to build extensive experience in machine learning, computational biology, and analysis of heterogeneous high-throughput genomic data. The research’s focus, directed towards the goal of developing personalized medicine based on big data from human cohorts, is on microbiome, nutrition, genetics, and their effect on health and diseases. A recipient of many awards, he was recognized also with the Overton Prize. Before joining the Weizmann Institute, He held an independent research position at Rockefeller University, New York. Professor Segal earned a BSc in Computer Science summa cum laude, from Tel-Aviv University, and a PhD in Computer Science and Genetics from Stanford University. To date, Professor Segal has over 150 published papers.